USPTO serial 79138125
VALNEVA
Reviewed by CopyMark Law Group
Reg. 4686292Status 706Registered
- Filing date
- Status date
- Registration date
- Feb 17, 2015
- Examiner
- BUONGIORNO, CHRISTOPHER L
- Law office
- TMEG LAW OFFICE 101
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with VALNEVA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Christina M. Licursi
Christina M. Licursi Wolf, Greenfield & Sacks, P.C.600 Atlantic AvenueBoston, MA 02210United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in industry, science and agriculture, except fungicides, herbicides, insecticides and parasiticides; molecules from biotechnologies, namely, proteins in raw material for industrial use, scientific or medical research; cells and cell lines for use in scientific, laboratory, or medical research; nucleic acids for laboratory use; proteins in raw material form for scientific and medical research; recombinant proteins in raw material form for scientific and medical research; Biomedical compounds, namely, peptide substrates and peptide antigens used in analyzing and detecting certain toxins for clinical or medical laboratory use; Biochemical preparations derived from blood serum used as growth promoters in tissue cultures and microbiological media; Biochemicals, namely, antibodies and fragments thereof for in vitro scientific or research use; Chemicals for use in biotechnological product development; Cultures of microorganisms other than for medical and veterinary use; Biological preparations and bacteriological preparations for use in cell cultures other than for medical or veterinary use | ACTIVE | — |
| 005 | Pharmaceuticals for human and veterinary use for the treatment of autoimmune diseases, inflammation, cancer, infectious diseases, diseases of the central nervous system, cardiovascular diseases, neurodegenerative and chronic diseases; antibodies and fragments thereof for use in disease testing; cell cultures, microorganisms and viruses for medical and veterinary use; diagnostic agents for medical, pharmaceutical and veterinary use; cells for medical or clinical use; culture media for cultivating microorganism cells for medical and veterinary use; adjuvants for medical or and veterinary use; pharmaceutical and veterinary preparations for medical, pharmaceutical and veterinary use, namely, preparations of encapsulated cells which release antibodies, living cells and microorganisms, vaccines, viral vectors, proteins, peptides, enzymes, nucleic acids or pharmaceutically active compounds for the treatment of cancer, auto-immune disorders, infectious diseases, inflammatory diseases, neurological and genetic disorders, bowel diseases, and digestion problems | ACTIVE | — |
| 042 | Scientific research services for medical purposes in the fields of autoimmune diseases, inflammation, cancer, infectious diseases, diseases of the central nervous system, cardiovascular diseases, neurodegenerative and chronic diseases; scientific research for medical, pharmaceutical and veterinary purposes in the fields of autoimmune diseases, inflammation, cancer, infectious diseases, diseases of the central nervous system, cardiovascular diseases, neurodegenerative and chronic diseases; scientific research, in particular, in the fields of biology, cellular and molecular biology, biotechnology, bacteriology, immunology, genetics, medicine, pharmacology, virology, chemistry; scientific research relating to vaccines, antibiotics and immunological products for human and veterinary use; research and development of new products for others; testing, analysis, and evaluation of the goods of others to assure compliance with industry standards in the scientific, medical and veterinary fields; development and design of laboratory instruments for scientific and industrial research, in particular, to obtain and prepare cells, cell lines, viruses, proteins, animal and human materials; development of vaccines, antibiotics and immunological products for human and veterinary use; scientific and technological services, namely, diagnostic and prognostic analyses in the fields of cells, cell lines, animal and human materials, microorganisms, molecules for scientific purposes; scientific research, namely, preparation of scientific experts opinions reports | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 4, 2026 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Jul 9, 2026 | RHRD | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED | — |
| May 9, 2025 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| May 9, 2025 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| May 5, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Dec 27, 2024 | ES71 | TEAS SECTION 71 RECEIVED | — |
| May 22, 2024 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Apr 25, 2024 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Feb 25, 2024 | RHRD | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED | — |
| Feb 17, 2024 | RHRD | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED | — |
| Feb 17, 2024 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Apr 7, 2023 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Nov 3, 2022 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Oct 15, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 1, 2022 | RHRD | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED | — |
| Nov 30, 2020 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Nov 30, 2020 | C75A | REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Nov 24, 2020 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jul 8, 2020 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Feb 17, 2020 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Sep 26, 2019 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Dec 13, 2018 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Dec 22, 2016 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jul 31, 2015 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jun 29, 2015 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jun 29, 2015 | FIMP | FINAL DISPOSITION PROCESSED | — |
| May 17, 2015 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Feb 17, 2015 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 2, 2014 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 2, 2014 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 12, 2014 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 29, 2014 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Oct 28, 2014 | ALIE | ASSIGNED TO LIE | — |
| Oct 9, 2014 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 9, 2014 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 9, 2014 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 9, 2014 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 9, 2014 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 24, 2014 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Apr 24, 2014 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 24, 2014 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 9, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 9, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 9, 2014 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 10, 2013 | RFNT | REFUSAL PROCESSED BY IB | — |
| Nov 20, 2013 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 20, 2013 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 19, 2013 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 16, 2013 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 15, 2013 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 13, 2013 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 13, 2013 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 11, 2013 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |